Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has been assigned a consensus rating of “Hold” from the seven ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $4.16.
Several equities analysts have recently issued reports on SNSS shares. Wells Fargo & Co upgraded Sunesis Pharmaceuticals from a “market perform” rating to an “outperform” rating and decreased their target price for the stock from $2.86 to $2.48 in a research report on Monday, December 11th. Cantor Fitzgerald set a $3.00 target price on Sunesis Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday, December 11th. Cowen restated a “hold” rating on shares of Sunesis Pharmaceuticals in a research report on Thursday, November 2nd. UBS Group started coverage on Sunesis Pharmaceuticals in a research report on Monday, November 20th. They set an “outperform” rating for the company. Finally, Oppenheimer started coverage on Sunesis Pharmaceuticals in a research report on Tuesday, November 21st. They set an “outperform” rating and a $7.00 target price for the company.
In other Sunesis Pharmaceuticals news, major shareholder Mpm Oncology Impact Management acquired 81,500 shares of the business’s stock in a transaction dated Monday, November 6th. The shares were acquired at an average price of $2.77 per share, for a total transaction of $225,755.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 10.21% of the stock is currently owned by insiders.
Sunesis Pharmaceuticals (NASDAQ:SNSS) opened at $5.82 on Friday. The stock has a market capitalization of $199.32, a PE ratio of -3.33 and a beta of 1.71. Sunesis Pharmaceuticals has a 12-month low of $1.82 and a 12-month high of $5.99. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of -0.34.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.06). During the same period in the prior year, the business posted ($0.62) earnings per share. equities research analysts predict that Sunesis Pharmaceuticals will post -1.58 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/02/04/sunesis-pharmaceuticals-inc-snss-given-average-recommendation-of-hold-by-analysts.html.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.